Neurological instability in ischemic stroke: relation with outcome, latency time, and molecular markers

dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Cirurxía e Especialidades Médico-Cirúrxicas
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e Medicina
dc.contributor.authorIglesias Rey, Ramón
dc.contributor.authorSilva Candal, Andrés da
dc.contributor.authorRodríguez Yáñez, Manuel
dc.contributor.authorEstany Gestal, Ana
dc.contributor.authorRegueiro, Uxía 
dc.contributor.authorMaqueda, Elena
dc.contributor.authorÁvila Gómez, Paulo
dc.contributor.authorPumar Cebreiro, José Manuel
dc.contributor.authorCastillo Sánchez, José Antonio
dc.contributor.authorSobrino Moreiras, Tomás
dc.contributor.authorCampos Pérez, Francisco
dc.contributor.authorHervella Lorenzo, Pablo
dc.date.accessioned2026-01-29T09:17:24Z
dc.date.available2026-01-29T09:17:24Z
dc.date.issued2021-06-24
dc.description.abstractThe National Institutes of Health Stroke Scale (NIHSS) is commonly used to evaluate stroke neurological deficits and to predict the patient’s outcome. Neurological instability (NI), defined as the variation of the NIHSS in the first 48 h, is a simple clinical metric that reflects dynamic changes in the area of the brain affected by the ischemia. We hypothesize that NI may represent areas of cerebral instability known as penumbra, which could expand or reduce brain injury and its associated neurological sequels. In this work, our aim was to analyze the association of NI with the functional outcome at 3 months and to study clinical biomarkers associated to NI as surrogate biomarkers of ischemic and inflammatory penumbrae in ischemic stroke (IS) patients. We included 663 IS patients in a retrospective observational study. Neutral NI was defined as a variation in the NI scale between − 5 and 5% (37.1%). Positive NI is attributed to patients with an improvement of > 5% NI after 48 h (48.9%), while negative NI is assigned to patients values lower than − 5% (14.0%). Poor outcome was assigned to patients with mRS ≥ 3 at 3 months. We observed an inverse association of poor outcome with positive NI (OR, 0.35; 95%CI, 0.18–0.67; p = 0.002) and a direct association with negative NI (OR, 6.30; 95%CI, 2.12–18.65; p = 0.001). Negative NI showed a higher association with poor outcome than most clinical markers. Regarding good functional outcome, positive NI was the marker with the higher association (19.31; CI 95%, 9.03–41.28; p < 0.0001) and with the highest percentage of identified patients with good functional outcome (17.6%). Patients with negative NI have higher glutamate levels compared with patients with neutral and positive NI (p < 0.0001). IL6 levels are significantly lower in patients with positive NI compared with neutral NI (p < 0.0001), while patients with negative NI showed the highest IL6 values (p < 0.0001). High glutamate levels were associated with negative NI at short latency times, decreasing at higher latency times. An opposite trend was observed for inflammation, and IL6 levels were similar in patients with positive and negative NI in the first 6 h and then higher in patients with negative NI. These results support NI as a prognosis factor in IS and the hypothesis of the existence of a delayed inflammatory penumbra, opening up the possibility of extending the therapeutic window for IS
dc.description.peerreviewedSI
dc.description.sponsorshipThis study was partially supported by grants from the Spanish Ministry of Science and Innovation (FEDER/Ministerio de Ciencia, Innovacion y Universidades-Agencia Estatal de Investigación-Proyecto SAF2017-84267-R), Xunta de Galicia (Consellería Educación, IN607A2018/3), Instituto de Salud Carlos III (ISCIII) (PI17/00540 and PI17/01103), Spanish Research Network on Cerebrovascular Diseases RETICS-INVICTUS PLUS (RD16/0019), and by the European Union FEDER program. Furthermore, T. Sobrino (CPII17/00027) and F. Campos (CPII19/00020) are recipients of research contracts from the Miguel Servet program of Instituto de Salud Carlos III. The sponsors did not participate in the study design, collection, analysis, or interpretation of the data, in writing the report, or in the decision to submit the paper for publication
dc.identifier.citationIglesias-Rey, R., da Silva-Candal, A., Rodríguez-Yáñez, M. et al. Neurological Instability in Ischemic Stroke: Relation with Outcome, Latency Time, and Molecular Markers . Transl. Stroke Res. 13, 228–237 (2022). https://doi.org/10.1007/s12975-021-00924-2
dc.identifier.doi10.1007/s12975-021-00924-2
dc.identifier.essn1868-601X
dc.identifier.urihttps://hdl.handle.net/10347/45565
dc.journal.titleTranslational Stroke Research
dc.language.isoeng
dc.page.final237
dc.page.initial228
dc.publisherSpringer
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/SAF2017-84267-R/ES/NANOSONDAS DIAPEUTICAS AVANZADAS PARA IMAGENES MOLECULARES: EVALUACION DE LA DISFUNCION ENDOTELIAL EN LA ISQUEMIA CEREBRAL
dc.relation.publisherversionhttps://doi.org/10.1007/s12975-021-00924-2
dc.rights© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectStroke
dc.subjectNeurological instability
dc.subjectLatency time
dc.subjectGlutamate
dc.subjectInterleukin
dc.titleNeurological instability in ischemic stroke: relation with outcome, latency time, and molecular markers
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number13
dspace.entity.typePublication
relation.isAuthorOfPublication79b322b7-4192-4335-aed0-4f9864bec97e
relation.isAuthorOfPublication04ab58ca-8895-4e3e-819d-42dd1dba36a4
relation.isAuthorOfPublication7e2808f2-a23b-498c-b742-61b88b44cdc9
relation.isAuthorOfPublication.latestForDiscovery79b322b7-4192-4335-aed0-4f9864bec97e

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2021_TransStrRes_Iglesias_Neurological.pdf
Size:
816.68 KB
Format:
Adobe Portable Document Format